Study of Diagnostic Value of Cyclooxygenase-2 and Matrix Metalloproteinases in Atherosclerosis
International Journal of Biochemistry Research & Review,
Background and Aim: Atherosclerosis is a chronic systematic disease where lesion (plaque) develops results in activation of inflammatory reaction that leads to arterial obstruction. Atherosclerosis is the underlying cause for many cardiovascular diseases (CVD) which were estimated with 42 percent of total death in Saudi Arabia while Coronary artery diseases (CAD) accounted for 35 percent of total chronic diseases death in Saudi Arabia by 2008. Risk factors that attribute in progression of atherosclerotic lesion and subsequent complications are smoking, high Low Density Lipoprotein –Cholesterol (LDL-C), high blood pressure, obesity and alcohol.
Materials and Methods: This study was carried on 20 healthy individuals as a control group, 15 patients with stable angina, 15 patients with recent myocardial infraction (MI) and 15 patient 24-hours post MI. All subjects were males with age 45±65 years and underwent exclusion/inclusion criteria. COX-2, MMPs levels were quantitatively measured by enzyme-linked immunosorbent assay (ELISA).
Results: There is insignificant differences in both COX-2 and MMP-2 levels among studied groups (P = 0.450 and 0.246 respectively) .On other hand, MMP-9 demonstrate a significant elevation in its level in studied groups (P = 0.014): its level significantly increase in stable angina (31.474 ± 12.188 ng/ml) compared to both control (9.920 ± 0.075 ng/ml) and Post MI groups (16.012 ± 13.852 ng/ml) (P = 0.001 and 0.004 respectively) and significantly increase in MI group (26.020 ± 14.792 ng/ml) when compared to both control (P = 0.006) and post MI (P = 0.038) groups.
Conclusion: We can conclude that both COX-2 and MMP-2 cannot be used as markers for diagnosis of stable angina or MI. While MMP-9 as it showed significant elevation in its level in MI and then decrease in post MI, it can be considered as a good marker for confirming the diagnosis of MI and post MI stage.
- Cardiovascular disease
- myocardial infarction
- matrix metalloproteinase-2
- matrix metalloproteinase-9
- creatinine kinase
How to Cite
Ross R. Atherosclerosis: A defense mechanism gone awry. The American Journal of Pathology. 1993;143(4):987–1002,.
Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Current Opinion in Pharmacology. 2004;4(2):16–123.
Zidar N, Dolenc-Strazar, Jeruc ZI, Jerse M, Balazic J, Gartner U, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovascular Pathology. 2007;16(5):300–304,.
Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of cox pathway in experimental myocardial infarction. Journal of Molecular and Cellular Cardiology. 2004; 37(1):71–77.
Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-_b in myocardium of patients with congestive heart failure circulation. 1998;98(2):100–103.
Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochemical Journal. 1989;259(2):315,.
Crofford LJ, Wilder RL, Ristim¨aki A, Sano H, Remmers EF, Epps HR T Hla, et al. Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbolester and corticosteroids. The Journal of Clinical Investigation. 1994;93(3):1095–1101,.
Mc Adam B, Catella-Lawson F, Mardini I, Kapoor S, Lawson J, FitzGerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase (cox)-2: The human pharmacology of a selective inhibitor of cox-2. Proceedings of the National Academy of Sciences. 1999;96(1):272–277 .
Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandine synthase in symptomatic atherosclerotic plaques as a basis of prostaglandine 2-dependent plaque instability. Circulation. 2001;104(8):921–927.
Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D, Ucchino S, et al. Association between prostaglandin e receptor subtype ep4 overexpression and unstable phenotype in atherosclerotic plaquesin human, Arteriosclerosis, thrombosis and vascular biology. 2005;25 (9):1925–1931.
Corcoran ML, Stetlerstevenso WGn, Dewitt DL, Wahl LM. Effect of cholera toxin and pertussis toxin on prostaglandin-h synthase-2, prostaglandin e2 and matrix metalloproteinase production by human monocytes. Archives of Biochemistry and Biophysics. 1994;310(2): 481–488.
Koki A, Khan NK, Woerner BM, Dannenberg A, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. 2002;177–184.
Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: Recent developments and a novel hypothesis, Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004;70(2):101–113.
Yang T, Singh I, Pham H, Sun D, Smart AJ, Schnermann B, Briggs JP, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. American Journal of Physiology-Renal Physiology; 1998.
Patrono C. The pgh-synthase system and isozyme-selective inhibition. Journal of Cardiovascular Pharmacology. 2006;47: S1–S6.
Jugdutt B, Basualdo C. Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling. The Canadian Journal of Cardiology. 1989;5(4):211–221.
Jugdutt BI. Effect of nitroglycerin and ibuprofen on left ventricular topography and rupture threshold during healing after myocardial infarction in the dog. Canadian journal of physiology and pharmacology. 1988;66(4):385–395.
Brown JR, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration after experimental myocardial infarction. The American journal of Cardiology. 1983;51(5):877–883.
Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, et al. Increased expression of 72-kd type iv collagenase (mmp-2) in human aortic atherosclerotic lesions. The American Journal of Pathology. 1996;148(1):121 .
Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110(13):1747–1753,.
Kieffer P, Giummelly P, Schjoth B, Carteaux JP, Villemot JP, Hornebeck W, Atkinson J. Activation of metalloproteinase- 2, loss of matrix scleroprotein content and coronary artery calcification. Athero- sclerosis. 2001;157(1):251–254.
Lucivero V, Prontera M, Mezzapesa D, Petruzzellis M, Sancilio M, Tinelli M, et al. Different roles of matrix metalloprotein ases-2 and-9 after human ischaemic stroke. Neurological Sciences. 2007;28(4): 165–170 .
Pasterkamp G, Schoneveld AH, Hijnen DJ, De Kleijn DP, Teepen H, Van Der Wal A, Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150(2):245–253 .
Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clinical Chemistry and Laboratory Medicine (CCLM). 2001;39(5):380–384.
Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation. 2005;111(14):1800–1805 .
Buraczynska K, Kurzepa J, Ksiazek A, Buraczynska M, Rejdak K. Matrix metalloproteinase-9 (mmp-9) gene polymorphism in stroke patients. Neuromolecular Medicine. 2015;17(4): 385–390 .
Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99(8):993–998.
Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, et al. Comparison of levels of serum matrix metalloproteinase- 9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. The American journal of Cardiology. 2006;97(2):175–180.
Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2006; 290(1):H232–H239 .
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacological Reviews. 2004;56(4):549–580 .
D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12–dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004; 50(10):3275–3285.
Jong G, Ma T, Chou P, Chang M, Wu C, Li P, et al. Serum mmp-9 activity as a diagnosing marker for the developing heart failure of post mi patients. Chinese Journal of Physiology. 2006;49(2):104.
Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions a. Annals of the New York Academy of Sciences. 1994;748 (1):501–507.
Fang L, Du XJ, Gao XM, Dart AM. Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clinical Science. 2010;119(4):175–183.
Carlo Ad. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncology Letters. 2013;5(5):1677–1681.
Brown RD, Jones GM, Laird RE, Hudson P, Long CS. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochemical and Biophysical Research Communications. 2007;362(1):200–205.
Kramsch DM, Franzblau C, Hollander W. The protein and lipid composition of arterial elastin and its relationship to lipid accumulation in the atherosclerotic plaque. Journal of Clinical Investigation. 1971; 50(8):1666–1677.
Suyasa IPE, Rina K, Widiana I. The association between matrix metalloproteinase-9 (mmp-9) with high sensitive troponin t (hs-tnt) in patient with acute myocardial infarction. Medicina-buenos Aires. 2015;46.
Abstract View: 57 times
PDF Download: 144 times